FDA Adverse Event Injury Summary report: N

SEPRAFILM (SODIUM HYALURONATE, CARBOXYMETHYLCELLULOSE) MEMBRANE

MDR report key: 1870882 · Received October 7, 2010

Report

Report Number
1220423-2010-00022
Event Type
Injury
Date Received
October 7, 2010
Date of Event
May 30, 2008
Report Date
June 3, 2008
Manufacturer
GENZYME BIOSURGERY (SEPRAFILM/PACK)
Product Code
MCN
PMA / PMN Number
P950034
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
PHYSICIAN

Narratives

Description of Event or Problem · 1

SMALL BOWEL OBSTRUCTION [SLURRY] [SMALL INTESTINAL OBSTRUCTION] ADHESIONS [SLURRY] [ADHESION]. CASE DESCRIPTION. SPONTANEOUS REPORT RECEIVED ON (B)(6) 2008 FROM A PHYSICIAN, VIA A GENZYME COMPANY REPRESENTATIVE REGARDING A FEMALE, PATIENT, INITIALS AND AGE UNKNOWN, WITH AN UNKNOWN MEDICAL HISTORY. THE PATIENT UNDERWENT A TOTAL LAPAROSCOPIC HYSTERECTOMY DURING WHICH SEPRAFILM SLURRY WAS USED. FIVE DAYS LATER, THE PATIENT EXPERIENCED SMALL BOWEL OBSTRUCTION AND WAS REOPERATED ON (B)(6) 2008. ON THIS NIGHT, THE PATIENT WAS ALSO FOUND TO "FULL OF ADHESION". THE PATIENT WAS DISCHARGED ON (B)(6) 2008 AND "SHE WAS DOING BETTER." THE PHYSICIAN STATED THAT THERE "MIGHT HAVE BEEN A PROBLEM WITH THE SLURRY" AND THAT THE SCRUB TECHNICIANS WERE "CONFUSED" AND EACH TIME THEY "MIX A DIFFERENT FORMULA." THE RELATIONSHIP BETWEEN SEPRAFILM AND THE EVENTS WAS UNKNOWN. AT THE TIME OF THIS REPORT, THE OUTCOME OF THE SMALL BOWEL OBSTRUCTION WAS NOT YET RECOVERED AND THE EVENT OF ADHESIONS WAS UNKNOWN. THE SEPRAFILM LOT NUMBER WAS UNKNOWN. NO FURTHER INFORMATION WAS PROVIDED. SEE MANUFACTURER CONTROL NUMBER (B)(4) FOR OTHER ADVERSE EVENTS FROM THIS SOURCE. MANUFACTURER'S COMMENT: THE BENEFIT-RISK RELATIONSHIP OF SEPRAFILM IS NOT AFFECTED BY THIS REPORT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 SEPRAFILM (SODIUM HYALURONATE, CARBOXYMETHYLCELLULOSE) MEMBRANE BIORESORBABLE ADHESION BARRIER MCN GENZYME BIOSURGERY (SEPRAFILM/PACK) UNK UNK

Patients

Seq Age Sex Outcome Treatment
1 UNK Hospitalization